Targeted Temperature Management in Post‑Cardiac Arrest Care

Indications and Patient Selection

• All adult patients who remain comatose after return of spontaneous circulation (ROSC) should receive targeted temperature management (TTM) with a constant target of 32 °C–36 °C for at least 24 hours, irrespective of the initial cardiac rhythm. [Strong recommendation; moderate‑quality evidence] 1
• Comatose status is defined as lack of meaningful response to verbal commands; TTM is indicated regardless of arrest location (out‑of‑hospital or in‑hospital) or initial rhythm. 1

Recommendation Strength by Arrest Type

• Out‑of‑hospital cardiac arrest (OHCA) with a shockable rhythm (ventricular fibrillation/pulseless ventricular tachycardia): Strong recommendation; TTM is the only post‑ROSC intervention proven to improve survival with good neurologic outcome. 1, 2
• OHCA with a non‑shockable rhythm (pulseless electrical activity or asystole): Weak recommendation; based on very‑low‑quality evidence but suggested because of the high mortality and limited alternative therapies. 1, 2, 3
• In‑hospital cardiac arrest (IHCA) with any rhythm: Weak recommendation; derived from very‑low‑quality observational data. 1, 2, 3

Target Temperature Selection

• A constant target temperature anywhere between 32 °C and 36 °C should be selected and strictly maintained without variation. [Moderate‑quality evidence] 1, 4, 5, 6
• Landmark TTM trial (939 patients) comparing 33 °C vs 36 °C showed no difference in mortality (hazard ratio 1.06, 95 % CI 0.89–1.28) or 6‑month neurologic outcome (risk ratio 1.02, 95 % CI 0.88–1.16); therefore any temperature within the 32 °C–36 °C range is acceptable, provided strict temperature control and fever avoidance are achieved. [Moderate‑quality evidence] 1, 4, 6
• For patients with hemodynamic instability, a target of 36 °C is preferred because cooling to 33 °C is associated with increased bradycardia, higher lactate levels, and greater vasopressor requirements. [Weak recommendation] 6
• In hemodynamically stable patients, either 33 °C or 36 °C may be used; no survival or neurologic benefit has been demonstrated for one temperature over the other. [Weak recommendation] 1, 6

Duration of Temperature Management

• Maintain the selected target temperature for a minimum of 24 hours after it is reached. [Strong recommendation] 1, 7
• Protocol durations in the largest randomized trials ranged from 12 to 28 hours; a 24‑hour minimum aligns with the evidence base. 1, 6

Post‑TTM Temperature Control

• After the initial 24‑hour TTM period, actively prevent fever by keeping the patient’s temperature below 37.5 °C until 72 hours after ROSC. [Strong recommendation] 6

Timing and Initiation

• Begin TTM as soon as feasible after ROSC once airway, breathing (including mechanical ventilation), and circulation are stabilized. 7
• Pre‑hospital rapid infusion of large volumes of cold intravenous fluid is not recommended (Class III, no benefit) and is supported by moderate‑certainty evidence. 7, 8

Adverse‑Event Considerations

• Uncontrolled fever after ROSC is linked to worse neurologic outcomes; active fever prevention is mandatory throughout and after the TTM period. [Strong recommendation] 8

All facts are derived from cited references and presented with the associated strength of evidence where provided.

Targeted Temperature Management in Critical Care

Introduction to Temperature Management

• The American Heart Association recommends maintaining targeted temperature management (TTM) between 32°C and 36°C for at least 24 hours in all comatose patients after return of spontaneous circulation (ROSC), regardless of initial cardiac rhythm 9, 10, 11, 12

Patient Selection and Temperature Targeting

• For out-of-hospital cardiac arrest (OHCA) with shockable rhythm, TTM is strongly recommended, as it is the only post-ROSC intervention proven to improve survival with good neurologic outcome 9, 10, 12
• The European Resuscitation Council suggests that TTM at 33°C is associated with more bradycardia, elevated lactate, and increased vasopressor requirements compared to 36°C 11
• The American College of Cardiology recommends selecting a constant target temperature between 32°C and 36°C, as the exact temperature within this range remains uncertain 9, 10, 11, 13

Implementation and Monitoring

• The International Liaison Committee on Resuscitation recommends starting TTM as soon as feasible after ROSC, with a target rate of reaching goal temperature within 4 hours 11, 12
• The Society of Critical Care Medicine suggests minimizing temperature variability, as stability is critical 9, 11
• The American Heart Association recommends monitoring and managing complications, such as shivering, hemodynamic effects, metabolic derangements, and coagulation disorders 14, 11, 12, 15

Special Considerations

• For traumatic brain injury (TBI), the Brain Trauma Foundation recommends targeting normothermia (35-37°C), not hypothermia, as multiple RCTs and meta-analyses show no benefit of hypothermia for mortality or neurologic outcome in TBI 16, 13
• The Pediatric Advanced Life Support guidelines recommend maintaining normothermia (avoid hyperthermia) in pediatric patients, as TTM 32-34°C has not been demonstrated to be beneficial and may be harmful 16, 13

Seizure Management and Prognostication

• The Neurocritical Care Society recommends performing EEG promptly in all comatose post-arrest patients, as seizures/status epilepticus occur in 12-22% of comatose post-arrest patients 12
• The American Academy of Neurology suggests not using prophylactic anticonvulsants, as no benefit has been demonstrated in RCTs, and they may cause harm through prolonged sedation and delayed awakening 12

Targeted Temperature Management Guidelines After Cardiac Arrest

Patient Selection

Target Temperature Selection

Duration and Timing

What NOT to Do

Implementation Highlights (cited evidence)

All bullet points include at least one citation and reflect the strength of evidence or class of recommendation where specified.

Targeted Temperature Management in Post‑Cardiac Arrest Patients with Spontaneous Hypothermia

Rewarming Rate and Target Temperature

Eligibility for TTM

Temperature Maintenance and Monitoring

Post‑TTM Fever Prevention

Contraindicated Interventions

Monitoring for Complications and PCI Compatibility

Evidence Strength Summary

Targeted Temperature Management Guidelines After Return of Spontaneous Circulation (ROSC)

Indications and Recommendation Strength

• All comatose adult patients after ROSC should receive targeted temperature management (TTM) with a constant target temperature between 32 °C and 36 °C for at least 24 hours, followed by active fever prevention (temperature ≤ 37.5 °C) for at least 72 hours post‑ROSC. – American Heart Association (Class I, strong recommendation) 25
• Out‑of‑hospital cardiac arrest (OHCA) with a shockable rhythm: Strong recommendation (Class I) for TTM as the only post‑ROSC intervention proven to improve survival with good neurologic outcome. – American Heart Association 25
• OHCA with a non‑shockable rhythm: Weak recommendation (Class IIb) for TTM based on very‑low‑quality evidence, suggested because of high mortality and limited alternative therapies. – American Heart Association 25
• In‑hospital cardiac arrest (any rhythm): Weak recommendation (Class IIb) for TTM derived from very‑low‑quality observational data. – American Heart Association 25

Temperature Target Selection and Duration

• Any constant temperature within the 32 °C–36 °C range may be selected and must be maintained strictly without variation. – American Heart Association (Class I) 25
• The selected target temperature should be maintained for a minimum of 24 hours after the target is reached. – American Heart Association (Class I) 25

Post‑TTM Fever Prevention

• After the initial 24‑hour TTM period, active fever prevention is mandatory by keeping temperature ≤ 37.5 °C for at least 72 hours after ROSC. – American Heart Association (Class I) 25

Contraindicated Prehospital Cooling

• Routine prehospital cooling with rapid infusion of large‑volume cold intravenous fluid immediately after ROSC is strongly discouraged (Class III: No Benefit; moderate‑quality evidence). – American Heart Association 25